Originally presented January 23, 2019 as part of the UNC Cancer Network Medical and Surgical Oncology Lecture Series. This Self-Paced, Online Course expired April 1, 2020.
This is a Non-Credit course and does NOT offer continuing education credits.
Presenters
Brandi Reeves, MD
Professor of Medicine
Malignant Hematology
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill
Matthew Foster, MD
Associate Professor, Clinical Research
Leukemia, Lymphoma, and Myeloma Program
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill
Best of ASH 2018: Myeloma and Leukemia/MDS
Each year, the American Society of Hematology (ASH) hosts a conference highlighting some of the latest hematologic oncology research. Join us as our speakers discuss some of the top presentations on Myeloma and Leukemia/MDS from this year’s ASH conference.
Learning Outcomes
- Compare the outcomes of previously untreated patients with chronic lymphocytic leukemia (CLL) who are treated with ibrutinib versus those treated with chemo-therapy
- Describe which patients with myelodysplastic syndromes may benefit from treatment with luspatercept
- Identify appropriate patients with myelodysplastic syndromes for iron chelation with defarasirox and list adverse outcomes that may be prevented by using this agent
Credits Offered
- 1.0 ANCC (CNE) hours of study.
- 1 ASRT Category A CE Credit
- 1.0 AMA PRA Category 1 Credit™
- 1.0 ACPE CE Credit
- General Participation
Requirements
To receive credit for this course, you must:
- Watch a lecture video recording.
- Complete the lecture post test and obtain a passing score of 80% or higher.
- Complete the course evaluation.
- Select credit type.
Estimated course completion time: 1 hour
Disclosures
This activity has been planned and implemented under the sole supervision of the course directors, in association with the UNC Office of Continuing Professional Development (UNC CPD). Dr. Thomas Shea consults for Spectrum Pharma and receives research support from Millennium, Otsuka, GSK, BMS, Novartis and Seattle Genetics. Dr. James Coghill, MD, and CPD staff have no relevant financial relationships with commercial interests as defined by the ACCME.
The speakers, Brandi Reeves, MD, and Matthew Foster, MD, have no relevant financial relationships with commercial interests as defined by the ACCME.
Accreditation
This is a Non-Credit course and does NOT offer continuing education credits.
Disclaimer
Please note: This course was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. Questions about personal health should always be referred to a physician or other health care professional.